Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Adeno associated virus (AAV) vectors manufacturing industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Therapeutic area trends
2.1.4 Application trends
2.1.5 Method trends
Chapter 3 AAV Vectors Manufacturing Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Expanding pipeline of gene therapy
3.2.1.2 Advancements in vectors production technology
3.2.1.3 Increased diversification of therapeutic areas
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.2.2.2 Production and scalability issues
3.3 Growth potential analysis
3.3.1 By therapeutic area
3.3.2 By application
3.3.3 By method
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Pipeline analysis
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic dashboard, 2022
Chapter 5 AAV Vectors Manufacturing Market Estimates and Forecast, By Therapeutic Area, 2018 - 2032 (USD Million)
5.1 Key trends, by therapeutic area
5.2 Neurological disorders
5.3 Metabolic disorders
5.4 Ophthalmic disorders
5.5 Muscular/Neuromuscular disorders
5.6 Infectious diseases
5.7 Bleeding disorders
5.8 Inflammation and fibrosis
5.9 Other therapeutic areas
Chapter 6 AAV Vectors Manufacturing Market Estimates and Forecast, By Application, 2018 - 2032 (USD Million)
6.1 Key trends, by application
6.2 Gene therapy
6.3 Vaccine
6.4 Cell therapy
6.5 Other applications
Chapter 7 AAV Vectors Manufacturing Market Estimates and Forecast, By Method, 2018 - 2032 (USD Million)
7.1 Key trends, by method
7.2 In vitro
7.3 In vivo
Chapter 8 AAV Vectors Manufacturing Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 F. Hoffmann-La Roche (Spark Therapeutics)
9.2 Biomarin Pharmaceutical
9.3 Oxford BioMedica plc
9.4 WuXi AppTec
9.5 YPOSKESI
9.6 Sarepta Therapeutics
9.7 Regenxbio Inc.
9.8 Audentes Therapeutics
9.9 4D Molecular Therapeutics
9.10 Ultragenyx Pharmaceutical Inc.
